CTLA4 and enterocolitis: Treatment of naïve Balb/c mice biweekly with Fc-effector anti-CTLA4 antibody for 7 weeks resulted in weight loss (figure 1A) associated with increased intestinal permeability (figure 1B) and severe enterocolitis (figure 1C–E).